{ }
001122334455554433221100
001122334455554433221100

lexicon sells rights to cardio drug to viatris amid restructuring efforts

Lexicon Pharmaceuticals has sold the rights to its cardio drug, sotagliflozin, to Viatris for $25 million upfront, with potential milestone payments of up to $200 million. This move comes as Lexicon restructures and aims to expand into Type 1 diabetes, with an FDA advisory panel set to review the drug's use in this area on October 31. The approval could unlock a $400 million U.S. market for the drug, which is currently marketed as Inpefa for heart failure and related conditions.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.